

Additional file 1

Table S1. CRISPR RNA oligo sequences used in this study. The tracrRNA was synthesized by IDT as a Ultramer RNA Oligo. All crRNAs were synthesized by Sigma Aldrich with HPLC purification.

Description	Target	Sequence (5'-3')
tracrRNA	n/a	CAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUG AAAAAGUGGCACCGAGUCGGUGCUU
crRNA-NT	none	CCAUAUCGGGGCGAGACAUGGUUUUAGAGCUAUGCUGUUUUUG
crRNA-EGFP	EGFP	GGGCGAGGAGCUGUUCACCGUUUUUAGAGCUAUGCUGUUUUUG
crRNA-PTEN	Human <i>PTEN</i>	UGUGCAUAUUUAUUACAUCGGUUUUUAGAGCUAUGCUGUUUUUG
crRNA-KRAS#5	Human <i>KRAS</i>	AGAGGAGUACAGUGCAAUGAGUUUUUAGAGCUAUGCUGUUUUUG
crRNA-KRAS#6	Human <i>KRAS</i>	UCUCGACACAGCAGGUCAAGGUUUUAGAGCUAUGCUGUUUUUG

Table S2. siRNA sequences used in this study.

Description	Target	Manufacturer (Cat #)	Sense Stand Sequence
siNeg	n/a	Qiagen (1027281)	n/a (pool)
siEGFP	EGFP	Invitrogen (1022064)	CGGCAAGCTGACCCTGAAGTTCAT
siPTEN	Human <i>PTEN</i>	Dharmacon (D-003023-05)	GUGAAGAUCUUGACCAA
siKRAS	Human <i>KRAS</i>	n/a	UUGACGAUACAGCUAAUUCAUA

Table S3. PCR primer sequences. These primers were used for PCR amplification of the CRISPR/Cas9 target site in each gene.

Description	Sequence (5'-3')
EGFP Forward	AAGCCCTTTGTACACCCTAAGCCTCC
EGFP Reverse	GCTTGTCGGCCATGATATAGACGTTGTG
PTEN Forward	CTCTGGAATCCAGTGTTTC
PTEN Reverse	GATCTTAAATGCTTTCACCCTGG
KRAS Forward	GCCATTTGTCCGTCATCTTTG
KRAS Reverse	GATGCAGTCTGGAGCAAGTTA

Table S4. Antibodies information.

Protein	Manufacturer (Cat #)	Dilution
EGFP	Santa Cruz (sc-8334)	1/500
PTEN	Cell Signaling (9188)	1/1,000
KRAS	Sigma Aldrich (WH0003845)	1/200
Vinculin	Sigma Aldrich (V9131)	1/10,000